Back to the Top


Name: Solanezumab
Synonyms: LY2062430
Therapy Type: Immunotherapy (passive) (timeline)
Target Type: Amyloid-Related (timeline)
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Discontinued)
Company: Eli Lilly & Co.
Approved for: None


Solanezumab is a humanized monoclonal IgG1 antibody directed against the mid-domain of the Aβ peptide. It recognizes soluble monomeric, not fibrillar, Aβ. The therapeutic rationale is that it may exert benefit by sequestering Aβ, shifting equilibria between different species of Aβ, and removing small soluble species of Aβ that are directly toxic to synaptic function. In preclinical research, a single injection of m266, the mouse version of solanezumab, reversed memory deficits in APP-transgenic mouse models while leaving amyloid plaques in place, raising the prospect of targeting the soluble pool of Aβ (Apr 2002 news story).


In Phase 1, single doses of 0.5, 1.5, 4.0, or 10.0 mg/kg of solanezumab were well-tolerated in healthy volunteers and 19 patients with mild to moderate AD. MRI showed no evidence of inflammation, vasogenic edema, or microhemorrhage. A multiple-dose study in Japan delivered a 400 mg dose to 33 patients with mild to moderate AD intravenously every one, four, or eight weeks, also without serious adverse events related to solanezumab. Pharmacodynamic biomarker studies found changes in plasma and CSF Aβ40, Aβ42, plasma pyro-Glu Aβ, and plasma and CSF N-terminally truncated Aβ, but not CSF total tau and phosphorylated tau.

In Phase 2, trials administering 100 to 1,600 mg per month of solanezumab for 12 weeks, and monitoring for safety and biomarker effects for one year, confirmed the antibody's safety and tolerability. Phase 2 showed dose-dependent increases of various Aβ species in plasma and CSF but no effects on the ADAS-Cog, i.e., no indication of clinical benefit.

In Phase 3, two trials, EXPEDITION-1 and -2, randomized 2,052 people with mild to moderate AD to receive infusions of 400 mg of solanezumab or placebo once a month for 80 weeks. Data analysis was conducted by the study sponsor and independently by the Alzheimer Disease Study Group. Solanezumab continued to be safe, but EXPEDITION overall showed no improvement on the primary outcome measures of ADAS-Cog11 and ADCS-ADL. However, a prespecified subgroup analysis of the EXPEDITION-1 trial showed that solanezumab reduced cognitive decline in mild AD when measured by ADAS-Cog 14, prompting the FDA to approve revision of the primary endpoint of EXPEDITION-2 to a single endpoint of cognition in patients with mild AD before the trial database was locked. That analysis saw a trend to improved cognition with solanezumab in people with mild AD, but it missed statistical significance. Statistically significant benefit was seen in a pooled analysis of patients with mild AD in both trials. Benefit for instrumental activities of daily living also was seen in the mild subpopulation. The benefit appeared late, grew over time, and thus is thought to be consistent with a disease-modifying effect. The effect size of the benefit is small, generally thought to be smaller than that of cholinesterase-inhibitor drugs (Doody et al., 2014). Nearly half of participants in these two trials had no cognitive decline during the study period (Ezzati et al., 2022).

In July 2013, Lilly started EXPEDITION-3, a 39-center Phase 3 trial in 2,100 patients with mild AD and demonstrated brain amyloid burden. In March 2016, Lilly announced that it would change the primary outcome for this trial. The original plan registered with regulatory agencies was to use a cognitive (ADAS-Cog 14) and a functional (ADCS-iADL) battery as co-primary outcomes; however, the new plan is to use ADAS-Cog as a single primary and ADCS-iADL as a secondary outcome. According to the company, this changed the trial's data analysis but not the conduct of the trial itself (see company release). On November 23, 2016, Lilly announced, based on top-line results, that solanezumab had missed its primary endpoint in this trial. Primary and secondary outcome results were trending in the direction of a treatment benefit, but effects were small and fell short of statistical significance. Lilly will not pursue FDA approval for solanezumab in mild AD (see company release). Trial results have been published  (Honig et al., 2018; Schwarz et al., 2019). A subsequent meta-analysis of data from the three EXPEDITION trials found that low-dose solanezumab slowed decline on cognitive and functional endpoints by 15 to 30 percent, meeting statistical significance (Holdridge et al., 2023). An analysis of MRI scans taken during EXPEDITION 1-3 trials found no effect on solanezumab on brain volume in these trials (Svaldi et al., 2022).

Solanezumab's safety record and indication of a small benefit in mild AD prompted its selection for two secondary prevention studies. In 2012, the Dominantly Inherited Alzheimer's Network Trials Unit (DIAN-TU) began conducting a five-year Phase 2/3 trial to test solanezumab and Roche's therapeutic antibody gantenerumab in 210 asymptomatic and very mildly symptomatic carriers of autosomal-dominant mutations in the Alzheimer's genes APP, presenilin-1, and presenilin-2. This study began as a two-year, Phase 2 biomarker study, and evolved into a Phase 3 registration trial with a cognitive endpoint measured after at least four years of treatment. Dosing began at 400 mg every four weeks, and was increased to 1,600 mg midway through the trial. 

On February 10, 2020, study investigators announced the trial had failed to meet its primary endpoint, showing no statistically significant treatment-related change on the DIAN Multivariate Cognitive Endpoint, a composite developed for this trial (Feb 2020 news). The study followed 194 participants for up to seven years; 50 received solanezumab, and 36 completed four years of treatment.

According to biomarker data presented at the 2020 AAT-AD/PD Focus Meeting, solanezumab treatment caused a steep increase in CSF Aβ42, indicating target engagement. Solanezumab did not alter tau biomarkers, and changed CSF neurofilament light concentrations for the worse. Participants in the trial were offered an open-label extension with high-dose gantenerumab, based on that antibody’s positive effects on imaging and other biomarkers in the DIAN-TU trial (Apr 2020 conference news; see also Wang et al., 2022). Peer-reviewed results were subsequently published (Jun 2021 news). Solanezumab caused no ARIA in this trial (Joseph-Mathurin et al., 2022).

In February 2014, the Alzheimer's Disease Cooperative Study began a three-year trial testing solanezumab in 1,150 asymptomatic or very mildly symptomatic people 65 and older who have biomarker evidence of brain amyloid deposition, i.e., who meet a diagnosis of Phases 2 or 3 of preclinical AD as proposed by the 2011 NIA-AA diagnostic research criteria (Sperling et al., 2011). Called A4, this secondary prevention trial uses the cognitive battery ADCS-PACC, which was developed to be sensitive at earlier clinical stages (Donohue et al., 2014). Amid a controversial leadership change, oversight of this trial moved from ADCS to the new Alzheimer's Therapy Research Institute at the University of Southern California. In June 2017, the study directors announced a quadrupling of the dose from 400 to 1,600 mg solanezumab or placebo given by IV every four weeks, based on results of the EXPEDITION program. Moreover, the A4s study length also increased to 4½ years.

In December 2015, Lilly began evaluating a subcutaneous formulation of solanezumab in a Phase 1 trial of 130 people. The trial was stopped in January 2017.

In June 2016, Lilly began a Phase 3 study in prodromal AD. Called ExpeditionPRO. It was to enroll 2,450 people with a clinical diagnosis of prodromal AD per IWG criteria, or of MCI due to AD per NAI-AA criteria, in up to 223 locations worldwide. Participants were to have a positive amyloid PET scan and score within a defined range on the MoCA and FCSRT tests. The trial started comparing a two-year course of a monthly infusion of solanezumab to placebo for change on the ADAS-Cog14 scale; 16 listed secondary outcomes ran the gamut from clinical, cognitive, functional, psychiatric, and global measures to biomarkers in blood, CSF, and PET scans for both amyloid and tau pathology. In January 2017, Lilly terminated this trial after enrolling only 26 participants.

The A4 trial finished in December 2022. On March 8, 2023, Lilly announced negative top line results, and the end of development for solanezumab (company release, March 2023 news). Solanezumab did not slow cognitive decline compared to placebo, nor did it clear plaque or stop amyloid accumulation. The placebo group did slightly better than the treatment group on the PACC and secondary endpoints, but the difference was not statistically significant. Results were published after peer review (Sperling et al., 2023).

For all solanezumab trials, see

Clinical Trial Timeline

  • Phase 2
  • Phase 2/3
  • Phase 3
  • Study completed / Planned end date
  • Planned end date unavailable
  • Study aborted
Sponsor Clinical Trial 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034
Eli Lilly & Co. NCT00329082
Eli Lilly & Co. NCT00749216
Eli Lilly & Co. NCT00904683
Eli Lilly & Co. NCT00905372
Eli Lilly & Co. NCT01148498
Eli Lilly & Co. NCT01127633
Eli Lilly & Co. NCT01760005
Washington University School of Medicine NCT04623242
Eli Lilly & Co. NCT01900665
Eli Lilly & Co. NCT02008357
Eli Lilly & Co. NCT02760602

Last Updated: 05 Feb 2024


No Available Comments

Make a Comment

To make a comment you must login or register.


Therapeutics Citations

  1. Gantenerumab

News Citations

  1. Topline Result for First DIAN-TU Clinical Trial: Negative on Primary
  2. In DIAN-TU, Gantenerumab Brings Down Tau. By a Lot. Open Extension Planned
  3. Paper Alert: DIAN-TU Solanezumab and Gantenerumab Data Published
  4. Legacy of A4 Secondary Prevention Study Goes Beyond Negative Result
  5. One-Shot Deal? Mice Regain Memory Day After Vaccination, Plaques Stay Put

Paper Citations

  1. . Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23;370(4):311-21. PubMed.
  2. . Application of predictive models in boosting power of Alzheimer's disease clinical trials: A post hoc analysis of phase 3 solanezumab trials. Alzheimers Dement (N Y). 2022;8(1):e12223. Epub 2022 Mar 14 PubMed.
  3. . Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. N Engl J Med. 2018 Jan 25;378(4):321-330. PubMed.
  4. . Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease. Alzheimers Dement (N Y). 2019;5:328-337. Epub 2019 Jul 30 PubMed.
  5. . Targeting amyloid β in Alzheimer's disease: Meta-analysis of low-dose solanezumab in Alzheimer's disease with mild dementia studies. Alzheimers Dement. 2023 Mar 22; PubMed.
  6. . Magnetic resonance imaging measures of brain volumes across the EXPEDITION trials in mild and moderate Alzheimer's disease dementia. Alzheimers Dement (N Y). 2022;8(1):e12313. Epub 2022 Jun 27 PubMed.
  7. . Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Alzheimers Dement (Amst). 2022;14(1):e12367. Epub 2022 Nov 3 PubMed.
  8. . Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease. Ann Neurol. 2022 Nov;92(5):729-744. Epub 2022 Oct 13 PubMed.
  9. . Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):280-92. Epub 2011 Apr 21 PubMed.
  10. . The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014 Aug;71(8):961-70. PubMed.
  11. . Trial of Solanezumab in Preclinical Alzheimer's Disease. N Engl J Med. 2023 Sep 21;389(12):1096-1107. Epub 2023 Jul 17 PubMed.

External Citations

  1. company release
  2. company release
  3. company release

Further Reading


  1. . Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol. 2010 Mar-Apr;33(2):67-73. PubMed.
  2. . Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement. 2012 Jul;8(4):261-71. PubMed.
  3. . Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease. Clin Neuropharmacol. 2012 Jan;35(1):25-9. PubMed.
  4. . Amyloid-Beta Solubility in the Treatment of Alzheimer's Disease. N Engl J Med. 2018 Jan 25;378(4):391-392. PubMed.
  5. . Mutual population-shift driven antibody-peptide binding elucidated by molecular dynamics simulations. Sci Rep. 2020 Jan 29;10(1):1406. PubMed.
  6. . Late-Stage Failures of Monoclonal Antibody Drugs: A Retrospective Case Study Analysis. Pharmacology. 2020;105(3-4):145-163. Epub 2020 Jan 7 PubMed.
  7. . Safety and efficacy of active and passive immunotherapy in mild-to-moderate Alzheimer's disease: A systematic review and network meta-analysis. Clin Invest Med. 2019 Mar 23;42(1):E53-E65. PubMed.
  8. . Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis. Ageing Res Rev. 2023 Sep;90:102012. Epub 2023 Jul 7 PubMed.